Welcome to our dedicated page for Lite Strategy news (Ticker: LITS), a resource for investors and traders seeking the latest updates and insights on Lite Strategy stock.
Lite Strategy, Inc. reports developments around a Litecoin-focused digital asset treasury strategy, with Litecoin (LTC) designated as its primary treasury reserve asset. News from LITS centers on fiscal results, active treasury operations, covered-call use on LTC holdings, capital allocation, and the company’s common stock repurchase authorization.
The company’s recent corporate history includes its rebrand from MEI Pharma, Inc. and Nasdaq ticker change from MEIP to LITS. Updates also reference the company’s transition away from its prior pharmaceutical profile, including the sale of the ME-344 clinical asset, and its disclosures around treasury strategy execution and governance.
Lite Strategy (Nasdaq:LITS) reported fiscal 2026 third quarter results, highlighting ongoing active treasury management using Litecoin (LTC) as its primary reserve asset.
The company generated $0.7 million in covered call net proceeds since October 2025, used alongside 35,250 LTC to repurchase 1,629,136 shares. It continues advancing pre-clinical pharmaceutical programs and plans to scale its options program and execute on a $25 million share repurchase authorization. Updated SEC guidance indicating LTC exhibits digital commodity characteristics supports Lite Strategy’s focus on LTC ecosystem growth.
Lite Strategy (Nasdaq: LITS) reported fiscal 2026 second quarter results for the period ended December 31, 2025, highlighting the launch of active treasury operations. The company generated approximately $600,000 in gross premiums from a new covered‑call program, started a $25 million share repurchase plan, and held $8.8 million in cash.
Management said proceeds from treasury operations funded the repurchase program and noted initiation of pre‑clinical pharmaceutical R&D as a potential monetization pathway.
Lite Strategy (NASDAQ: LITS) reported first quarter fiscal 2026 results and outlined a strategic pivot to a Litecoin-based digital asset treasury. Key actions include a $100 million PIPE raised in July 2025, the acquisition of 929,548 LTC tokens as a primary reserve asset, a strategic partnership with GSR, and a rebrand from MEIP to LITS with a new ticker and website.
The company also announced a $25 million share repurchase program, reported $12.21 million in working capital and no outstanding debt, and completed the sale of its clinical asset ME-344 (WE-868) to Aardvark Therapeutics.
Lite Strategy (NASDAQ: LITS) announced on October 29, 2025 that its Board authorized a $25 million share repurchase program effective immediately. The program permits open-market and negotiated buybacks and may be executed under a future Rule 10b5-1 trading plan to allow purchases outside normal trading windows. The company said repurchases will be funded from available working capital and that timing and amounts will depend on market conditions; the program has no set price targets or timetable and may be suspended or terminated. Management highlighted flexibility to buy shares when trading below mNAV and to sell via its at-the-market offering when shares trade at a premium to mNAV.
Lite Strategy (NASDAQ: LITS) marked the 14th anniversary of Litecoin on October 16, 2025, highlighting Litecoin’s longevity as the second-longest-running blockchain and its transaction history.
Lite Strategy says it is the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, positioning LITS as a regulated, public-market vehicle for institutional exposure to Litecoin. Management frames the move as an immediate alternative while some digital asset ETFs remain pending amid an ongoing government shutdown.
MEI Pharma (NASDAQ:MEIP) announced its corporate rebranding to Lite Strategy, Inc. and will change its ticker to LITS effective September 11, 2025. The transformation reflects the company's strategic pivot to digital asset treasury management, focusing on Litecoin (LTC) as its primary reserve asset.
The company has already secured over $100 million in LTC with guidance from Litecoin creator Charlie Lee, who serves on the board, and GSR Ventures. While embracing this new direction, Lite Strategy continues to maintain its pharmaceutical pipeline, evaluating development opportunities for voruciclib and zandelisib.